Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemnifosbuvir in high-risk outpatients with COVID-19
NL-OMON53424Phase 3Not yet recruiting
- Sponsor
- Atea Pharmaceuticals
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bemnifosbuvir with Placebo (2 arms). Primary endpoint: All-cause hospitalization or all-cause death through Day 29. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON53424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53424.